baber/WOPTO huggingface dataset:
Patent JP-2872371-B2 (JP)
IPC: C10B45/00
Filed: 1990-08-31
Granted: 1999-03-17
Abstract: In a stationary gas jumper arrangement (6) for a coke oven with adjacent coke oven chambers (2, 2',...), each of which has a gas opening (5, 5',...), the gas jumper arrangement (6) covers gas openings (5, 5') of two neighbouring coke oven chambers (2, 2') in each case with one cover chambers (7, 7') and the two cover chambers (7, 7') are connected line-wise by a jumper pipe (9), and covers (8, 8') covering the gas openings (5, 5') during charging of a coke oven chamber (2, 2') can be moved within the cover chambers (7, 7') by means of an actuation device (12) from an open position into a closed position and set into rotary motion. 
<??>To ensure tightness of the gas openings (5, 5') with the covers (8, 8') put in place even in the event of major pressure fluctuations and to allow inertisation of the gas jumper arrangement (6), both the covers (8, 8') and the rim of each gas opening (5, 5') each have a sealing surface (24, 24', 25, 25') of the type of a valve seat, which sealing surfaces fit one another and are pressed against one another in the closed position of the cover (8, 8'), and a gas line (10) feeding an inert gas such as nitrogen leads into the gas jumper arrangement (6) and the latter is subjected, with the covers (8, 8') closed, to an inert gas pressure which is above the pressure within the coke oven chambers. 
<IMAGE>
Patent JP-H0211570-B2 (JP)
IPC: A61K9/72
Filed: 1984-11-07
Abstract: The present invention relates to a device or kit and a method for the inhalation administration of gangliosides and inner ester ganglioside derivatives useful for the treatment of various nervous disorders, such as those resulting from accidents or diseases which have damaged the nervous tissue.
Patent JP-2732399-B2 (JP)
IPC: B01J23/64
Filed: 1987-09-29
Granted: 1998-03-30
Abstract: A catalytic process for the generation of hydrogen by the partial oxidation of hydrocarbons, especially alkanes such as methane or hexane. The preferred catalyst system comprises from 0.01 to 5wt% platinum and from 1 to 15wt% chromium oxide supported on a refractory solid such as silica. Also a reactor for effecting the process in which the reactants are injected into or amongst the catalyst system and a technique for starting the process at ambient temperature by introducing an initiating compound such as methanol into the catalyst system.
Patent JP-2541484-B2 (JP)
IPC: G10L19/04
Filed: 1993-11-19
Granted: 1996-10-09
Abstract: PURPOSE:To make a receiver on the side of a speech decoding device hardly feel unnatural by forcibly updating a background noise when a background noise deciding circuit detects variation in characteristics of an input speech signal in a voiceless state. CONSTITUTION:The background noise update decision circuit 20 detects whether or not the input speech signal varies in characteristics in the voiceless state according to a synthesis filter coefficient and a frame energy value and outputs the result to a control circuit 17. If a voiced/voiceless sound decision circuit 14 detects the voiceless state when a speech encoding circuit 15 is in operation, the control circuit 17 encodes the current frame as a background noise frame and then stops the operation of the speech encoding circuit 15 temporarily, and, in the case where a voiced state is detected when the speech encoding circuit 15 is in the stop state, the operation of the speech encoding circuit 16 is restarted. Thus, when the background noise update decision circuit 20 detects the input speech signal varying in characteristics, the background noise is forcibly updated.
Patent JP-H0257942-B2 (JP)
IPC: A61M15/00
Filed: 1986-12-05
Abstract: An inhaler in use for inhaling pharmaceutical powdered preparations through mouth and making the same reach a trachea, bronchi and pulmonary cells. The inhaler has a general form bent at a predetermined angle, preferably, at 60 degrees, comprising a hollow body (1), a capsule holding portion (2) for receiving and holding a capsule (3), and an inhaling section (9). The capsule holding portion (2) is rotated relatively to the hollow body (1), whereby the capsule (3) is divided into two including a barrel and a head, so that the powdered preparations can fall into the hollow body (1). The powdered preparations, which have fallen into the hollow body (1) can be inhaled into a human body together with intake air flowing in through air flow-in openings provided in the capsule holding portion (2) by breathing with the mouth being applied to the inhaling section. The capsule barrel which has fallen into the hollow body (1) is prevented from being inhaled into the human body due to the presence of a porous member (13).
Patent JP-3489082-B2 (JP)
IPC: A61K8/00
Filed: 1991-10-30
Granted: 2004-01-19
Abstract: Use of an active quantity of nicotinamide-adenosine-dinucleotide (NAD) and/or of its phosphate ester (NADP) in topical application. The NAD and/or the NADP can be advantageously encapsulated in vesicles with a lamellar lipid structure. This composition can be employed for protecting the skin against solar irradiation.
Patent JP-H0351182-B2 (JP)
IPC: A61F2/38
Filed: 1985-11-29
Abstract: PCT No. PCT/DE85/00505 Sec. 371 Date Jul. 23, 1986 Sec. 102(e) Date Jul. 23, 1986 PCT Filed Nov. 29, 1985 PCT Pub. No. WO86/03117 PCT Pub. Date Jun. 5, 1986.The invention relates to knee joint endoprosthesis consisting of a femur part provided with two skid surfaces leaving a free space between each other, said surfaces being connected with each other in front and having their curvature increasing from the front towards the rear and being curved also on planes perpendicular to said curvature; a tibia part having two surfaces on which the skid surfaces ride in a sliding manner, with an elevation being disposed between said two surfaces; and of artificial connecting means for keeping the two parts of the prosthesis together. The invention lies in the fact that the outer surface (2) of the tibia part is largely plane on a center sectional plane from the front to the rear; that the inner surface (1) of the tibia part is slightly concave on a center sectional plane from the front to the rear; that the slope (6) of the elevation (3; 4) to the outer surface (2) is flatter than the slope (5) of the elevation (3; 4) to the inner surface (1); and that the parts of the prosthesis are kept together by two ending, non-flexible bands, of which a first band extends from the front center of the tibia part upwardly and on the outside and inclined rearwardly to the femur part, and of which bands a second band extends from the rear center of the tibia part upwardly and on the inside and inclined to the front to the femur part, whereby the bands are taut when the knee is stretched, and slightly relaxed in the unstressed state when the knee is bent. In said way, the motions of the prosthesis conform closer to the natural motions than heretofore.
Patent JP-3091870-B2 (JP)
IPC: C07K16/32
Filed: 1990-12-13
Granted: 2000-09-25
Abstract: The present invention relates to an oncoprotein specific for hepatocellular carcinomas and to a nucleotide sequence that codes for such a protein. The invention further relates to screening and diagnostic methodologies (and kits based thereon) that make use of the oncoprotein (or antibodies specific for same) and the nucleotide sequence.
Patent JP-2721434-B2 (JP)
IPC: C07F9/6561
Filed: 1993-06-18
Granted: 1998-03-04
Abstract: Crystal D or E of 1-hydroxy-2-(imidazo[1,2-a]-pyridin-3-yl)ethane-1,1-bis(phosphonic acid) monohydrate having specified lattice spacing and relative intensity in the powder X-ray diffraction spectrum obtained by using Cu-K alpha  radiation and a dehydration peak temperature of 135-149 DEG C or 160-170  DEG C according to TG-DSC thermogravimetric analysis; and a solid pharmaceutical preparation containing the same. The crystals are useful for producing a stable solid preparation of the above compound which has an excellent drug efficacy for diseases wherein increased bone resorption participates, such as osteoporosis.
Patent JP-H0723364-B2 (JP)
IPC: C07D317/28
Filed: 1984-08-02
Abstract: 1-piparazinecarboxamide derivatives are described which have the formula (I) 
<CHEM>
 wherein R1 is a member selected from hydrogen, halogen or trifluoromethyl;
 wherein X is selected from:
 > CO (Ia)
 > CHOH (Ib) > CHOR8 (Ib min ) > CHOCOR8 (Ib sec )
 > CH2 (Ic)
 > C = CR6R7 (Id)
 > CH - CHR6R7 (Ie) 
<CHEM>
 wherein R2 and R3 are the same or different and selected from hydrogen or lower alkyl;
 wherein Z ist either oxygen or sulfur;
 wherein Y is -NR4R5, where R4 and R5 are the same or different and selected from hydrogen, alkyl, alkenyl, cycloalkyl, aryl, aryl-(lower alkyl), or R4 and R5 may together with the N-atom form a 5- or 6- or 7-membered satin red ring, where one of the carbon atoms may be exchanged for O, NR8 or NCOR8;
 wherein R6 and R7 are the same or different and selected from hydrogen or lower alkyl;
 wherein R8 is lower alkyl or lower alkenyl;
 with the proviso that when X is > CO, then R4 is hydrogen and R5 is different from hydrogen. 
<??>Pharmaceutical compositions containing said 1-piperazinecarboxamide derivates are also described. 
<??>The derivatives are useful in treating mental disorders and/or aggression in man and in treating aggression in animals and for calming animals. 
<??>Different processes for preparing the derivatives are also described.
Patent JP-3344587-B2 (JP)
IPC: G03B21/00
Filed: 1994-06-28
Granted: 2002-11-11
Abstract: A projection system for projecting computergraphic images onto a domed or spherical viewing surface. An intense beam of coherent light is color and intensity modulated and deflected in a pair of cartesian axes prior to being projected through a wide angle lens array. Because the light beam is deflected before entering the wide angle lens array, greater angles of deflection are possible. The images are generated by rapidly changing the deflection of an intense spot of light which is projected onto the viewing surface at a rate above the viewer's flicker rate. This wide angle lens array may include a scan flattening lens array by which the image can be focused onto a spatial image focal plane before it is projected through a wide angle lens.
Patent JP-3248533-B2 (JP)
IPC: G01N29/22
Filed: 1994-07-04
Granted: 2002-01-21
Abstract: PCT No. PCT/SE94/00659 Sec. 371 Date Jan. 5, 1996 Sec. 102(e) Date Jan. 5, 1996 PCT Filed Jul. 4, 1994 PCT Pub. No. WO95/02181 PCT Pub. Date Jan. 19, 1995The present invention is drawn to a system to be used for measuring NO levels in exhaled breathing air. The system comprises: (i) a face mask that tightly covers the nose and/or mouth of the individual that the mask is intended to be used on; (ii) an inlet unit for inhaled breathing air, (iii) an outlet unit for exhaled breathing air, (iv) a non-rebreathing valve through which inhaled and exhaled breathing air, respectively, passes, and (v) a measuring unit for NO connected to the outlet unit. The present invention furthers encompasses a method for the diagnosis in mammals of inflammatory conditions in the airways. The characteristic feature is that nitric oxide NO is measured in exhaled breathing air and a found abnormal level is taken as an indication of an inflammatory condition in the airways.
Patent JP-3204667-B2 (JP)
IPC: C07F9/6553
Filed: 1992-03-11
Granted: 2001-09-04
Abstract: PCT No. PCT/CH92/00049 Sec. 371 Date Nov. 13, 1992 Sec. 102(e) Date Nov. 13, 1992 PCT Filed Mar. 11, 1992 PCT Pub. No. WO92/16536 PCT Pub. Date Oct. 1, 1992.Novel, racemic and optically active phosphorus compounds of the formula   <IMAGE> I  wherein R signifies lower alkyl, lower alkoxy or a protected hydroxy group, R1 signifies a five membered heteroaromatic ring, R2 stands for lower alkyl or lower alkoxy and n represents the number 0, 1 or 2, are described. The compounds of formula I serve in the form of complexes with a metal of Group VIII as catalyst for asymmetric hydrogenations and for enantioselective hydrogen displacements in prochiral allylic systems.
Patent JP-H0229841-B2 (JP)
IPC: F04C2/00
Filed: 1985-10-02
Abstract: A rotary engine in which the expansion pressure of a working gas is converted into a mechanical rotary movement consists of an inner engine element with an outer circumferential surface and an outer engine element which surrounds the inner element and has an inner circumferential surface, the two surfaces being disposed closely adjacent and facing each other. Disposed at, for example, the inner surface are three spaced projections, which transmit the expansion pressure of the gas to the inner element, and three expansion chambers between the projections. Four reaction members, which are each movable into the expansion chambers in turn and transmit the gas expansion pressure to the outer element, are mounted at the circumferential surface of the outer element. The two circumferential surfaces have the form of complementary annular surfaces, wherein in cross-section the inner surface has the shape of a concave, parabola-like curve and the outer surface the shape of a convex, parabola-like curve. The surfaces extend parallel to each other with close sliding fit up to their outer edges.
Patent JP-3529134-B2 (JP)
IPC: A61K39/00
Filed: 1993-07-23
Granted: 2004-05-24
Abstract: The present invention is concerned with a Feline Herpesvirus (FHV) mutant comprising a heterologous gene or foreign DNA inserted into a section of the FHV genome. The invention also relates to a vector vaccine comprising a recombinant FHV mutant which expresses a heterologous polypeptide derived from a feline pathogen and a pharmaceutically acceptable carrier and induces an immune response in an inoculated host against both FHV and the feline pathogen.
Patent JP-3310289-B2 (JP)
IPC: C12N9/10
Filed: 1993-07-30
Granted: 2002-08-05
Abstract: The invention provides a new nerve-derived transglutaminase enzyme that converts immune-derived IL-2 to dimeric IL-2 having oligodendrocyte cytotoxic activity. Both the nerve-derived transglutaminase and the dimeric mammalian, e.g. human, IL-2, are for use as active ingredients in pharmaceutical compositions for inducing and facilitating regeneration of injured nerves of the central nervous system in mammals.
Patent JP-3204668-B2 (JP)
IPC: C07F9/42
Filed: 1992-03-12
Granted: 2001-09-04
Abstract: PCT No. PCT/CH92/00050 Sec. 371 Date Nov. 13, 1992 Sec. 102(e) Date Nov. 13, 1992 PCT Filed Mar. 12, 1992 PCT Pub. No. WO92/16535 PCT Pub. Date Oct. 1, 1992.Novel, racemic and optically active phosphorus compounds of the formula  (* CHEMICAL STRUCTURE *) I wherein R signifies lower alkyl, lower alkoxy or protected hydroxy, R1 signifies lower alkoxy, phenoxy, benzyloxy, chlorine or bromine, R2 stands for lower alkyl or lower alkoxy and n represents the number 0, 1 or 2, are described. These compounds are valuable intermediates in the manufacture of not only known, but also novel diphosphine ligands.
Patent JP-3468768-B2 (JP)
IPC: H04B3/23
Filed: 1992-10-28
Granted: 2003-11-17
Abstract: The operation of an echo canceller (4A to 4D) is controlled by a call control (2) of a telephone exchange over an internal control bus (3, 5) of the telephone exchange. The exchange then attends to the necessary signalling and the echo canceller does not need to know how the associated signalling is routed in the telephone network.
Patent JP-3707560-B2 (JP)
IPC: B65D8/20
Filed: 1995-08-23
Granted: 2005-10-19
Abstract: Closing of a metal container and the like using a special end closure. The open end portion of a container is outwardly folded to define a supporting ledge and a seaming or curling flange for the end closure. Such flange is folded or rolled inwardly to capture an end closure including a plastic frame that defines a dispensing opening and has bonded thereto an end panel to be peeled back to allow dispensing of product. A seaming flange is folded about a peripheral portion of an outer boundary of the frame member and then the two are enfolded generally flat above the supporting ledge of the container to form an inwardly directed seam. A modified end closure comprises a molded plastic frame member which matches the configuration of a ledge portion of the container so the seaming flange and peripheral border portion of the frame member can be rolled together in an inwardly directed curl. The closing operations can be performed without axial pressure on the container wall so they can be thinner than normal. Inwardly directed seams and curls protect the plastic end closure from damage caused by closing tools because dies and/or chucks contact the flange portion of the container rather than the end closure. A seal between the inwardly turned seam or curl and the border portion of the frame member can be enhanced by applying heat during formation thereof or during retorting of the container and product.
Patent JP-3859239-B2 (JP)
IPC: C12Q1/00
Filed: 1998-07-15
Granted: 2006-12-20
Abstract: The present invention is to provide a concentration measuring apparatus and a test strip for the concentration measuring apparatus, whereby a component to be measured can be measured by the test strip fit to the target component to be measured.  A type judgement electrode (104) is provided separately from a positive electrode (102) and a negative electrode (103) in a measuring apparatus (101) so as to judge the type of a set test strip with the measuring apparatus. Thus only when a test strip (115) matching the measuring apparatus is set, the type judgement electrode is electrically connected to a terminal of the set test strip, enabling the measuring apparatus to measure a component to be measured in a liquid test sample. A measuring apparatus (251) detects a calibration curve information selection change for selecting a calibration curve information corresponding to a production lot of the set test strip thereby to compensate for an error in a measured concentration value of the component.
Patent JP-4309475-B2 (JP)
IPC: A61K31/34
Filed: 1997-08-13
Granted: 2009-08-05
Abstract: Compounds of formula Iwherein R1 is 1-2C-alkoxy optionally substituted by flourine, R2 is methyl, 1-methylethyl, 3-7C-cycloalkyl or 3-7Ccycloalkylmethyl and Ar is a pyridyl which is optionally di-halo substituted.
Patent JP-3477196-B2 (JP)
IPC: A61K47/48
Filed: 1990-07-31
Granted: 2003-12-10
Abstract: A process for extending the half-life in vivo by a biologically active protein or peptide, characterized by covalently coupling said protein or peptide to a polypeptide fragment capable of binding to a serum protein, whereby when administering the resulting protein or peptide congugate its binding to the serum protein results in extended biological activity; the use of the protein or peptide conjugate above for manufacturing a medicament which, when administered to a mammal including man, shows extended half-life in vivo; and a method of therapeutic or prophylactic treatment.
Patent JP-3378007-B2 (JP)
IPC: C01D17/00
Filed: 1993-11-10
Granted: 2003-02-17
Abstract: PCT No. PCT/EP93/03143 Sec. 371 Date Jul. 17, 1995 Sec. 102(e) Date Jul. 17, 1995 PCT Filed Nov. 10, 1993 PCT Pub. No. WO94/11303 PCT Pub. Date May 26, 1994The method of making a high density saline cesium and rubidium solution includes comminuting uncalcined pollucite and/or calcined lepidolite to a grain size of less than 0.1 mm; combining the comminuted material in the presence of water with Ca(OH)2 at a mol ratio of SiO2 to CaO of not less than 1:2; hydro-thermally decomposing at a temperature of 200 DEG  to 280 DEG  C., a pressure of 20 to 40 bar and with a suspension density of 4 to 15% by weight for from 1 to 3 hours to form a suspension containing insoluble solids; filtering the insoluble solids and washing to form a filtrate and concentrating the filtrate; blowing carbon dioxide into the concentrated filtrate to precipitate calcium carbonate and lithium carbonate and filtering the concentrated filtrate to separate the precipitated carbonates from a remaining solution; and then adding an acid or acid anhydride to the remaining solution until the pH of the remaining solution reaches about 6 and concentrating by evaporation to form the high density saline cesium and rubidium solution.
Patent JP-2918063-B2 (JP)
IPC: C25B3/28
Filed: 1990-08-28
Granted: 1999-07-12
Abstract: PCT No. PCT/DE90/00658 Sec. 371 Date Feb. 28, 1992 Sec. 102(e) Date Feb. 28, 1992 PCT Filed Aug. 28, 1990 PCT Pub. No. WO91/03442 PCT Pub. Date Mar. 21, 1991.A process for separation of mixtures of partially- or perfluorinated hydrocarbon compounds, which optionally contain additional chain members from the heteroatom group nitrogen, oxygen, boron, phosphorus and sulfur and/or can be substituted by further halogen atoms, characterized in that such partially- or perfluorinated compounds, which have an acyclic straight-chain structure and a critical molecule diameter in the range from 4 to 7 ANGSTROM  or are substituted by residues with a straight-chain acyclic structure and with a critical molecule diameter in the range from 4 to 7  ANGSTROM , of such partially- or perfluorinated compounds, which have no straight-chain acyclic residues, and whose critical molecule diameter amounts to at least 1.1-fold times the that of the aforementioned straight-chain acyclic residues, in liquid or gaseous phase are separated in that a mixture or a solution of the mixture in an inert organic solvent, the molecular diameter of which is larger that of the aforementioned straight-chain acyclic residue, is contacted with an amount of a molecular sieve sufficient for adsorption, the average pore diameter of which lies in the range of the critical molecule diameter of the aforesaid acyclic residue or up to 30% less, separating the molecular sieve laden predominantly with compounds containing acyclic residues, and desorbing the compounds adsorbed on the molecular sieve.
Patent JP-3684371-B2 (JP)
IPC: A61K38/00
Filed: 1996-12-13
Granted: 2005-08-17
Abstract: The present invention comprises an endothelial inhibitor and method of use therefor. The endothelial cell proliferation inhibitor is a protein having a molecular weight of approximately 14 kD and having a N-terminal sequence of GPVGAGEPKCPLMVKVLDAV, that has the ability to inhibit endothelial cell proliferation in in vitro assays.
Patent JP-3247894-B2 (JP)
IPC: C03C3/087
Filed: 1994-05-03
Granted: 2002-01-21
Abstract: A neutral, generally green-gray low transmittance (no more than 25 luminous transmittance) soda-lime-silica glass has reduced solar energy transmittance when provided with the following colorant constituents in percent by weight: -Fe2O3 (total iron) 1.3-2   -NiO 0.01-0.05 -CoO 0.02-0.04 -Se 0.0002-0.003  -  The glass has a ferrous value in the range of 18 to 30.
Patent JP-3688301-B2 (JP)
IPC: A62B18/08
Filed: 1997-04-14
Granted: 2005-08-24
Abstract: An inhalation/monitoring device is disclosed which has a headpiece adapted to fit a user which include an arcuate support member and ear members which can include a loudspeaker. A face piece is pivotably mounted to the support and includes a fluid chamber positionable over the user's nose for delivery of a gas such as an anesthesia or containing a monitoring device.
Patent JP-4596571-B2 (JP)
IPC: A61K31/44
Filed: 1998-04-29
Granted: 2010-12-08
Abstract: The present invention relates to 6-substituted 1,2,4a,5a,8a,8b-hexahydro- and 1,2,3,4,4a,5a,8a,8b-octahydro-6H-pyrrolo[3',4':4,5]furo[3,2-b]pyrid-8(7H)-one derivatives of the general formula (I) and their saltsin whichthe radicals R1, R2, R3, R4, B and A are each as defined in the description, to processes for their preparation and to their use for controlling endoparasites.